The EPN Scanner is only available for purchase in the European Economic Area and European Free Trade Association Countries.

How does the Electro Pulmonary Nodule Scan work?
It is not known precisely why malignant cells have a different dielectric constant than non-malignant tissues. Proposed mechanisms include altered ionic channels in cell membranes, different metabolic rates and changes in water content. Regardless of the exact mechanism causing the change in the dielectric constant, the EPN Scan uses this disparity in bioconductance to offer additional information for evaluating lung nodules.
Can the Electro Pulmonary Nodule Scan be used on areas of the body other than the lung?
Bioconductance testing has been used to assess for malignancy in other tissues, such as in the breast, cervix, thyroid and lymph nodes. The EPN Scan, however, is designed to assess patients with lung nodules and has not been tested on other potential cancer sites.
How do pneumonia and other pulmonary pathologies alter the Electro Pulmonary Nodule Scan result?
The EPN Scan may be influenced by inflammation. Patients with active infection, chronic inflammation or who are receiving high-dose systemic anti-inflammatory medication (i.e. corticosteroids) have been excluded from clinical studies of the EPN Scan. Patients receiving an EPN Scan will have had a CT scan to identify a lung nodule. Prior to an EPN Scan, patients should also be screened for active infection and/or chronic inflammatory conditions. It is not known how such conditions may affect the EPN Scan result.
Can the Electro Pulmonary Nodule Scan be used as a screening tool prior to LDCT scanning?
The EPN Scan was not studied as a screening test. It is to be used in assessing the likelihood of malignancy in pulmonary nodules identified by CT scanning which are suspicious for lung cancer.
How do size, location and radiologic appearance of a lung nodule affect Electro Pulmonary Nodule Scan results?
The EPN Scan assesses the bioconductance of the chest in patients with a nodule and produces a numeric score suggesting a higher risk of malignancy or increased likelihood of benignity. The EPN Scan does not assess the size, location or radiographic appearance of a lung nodule.
Can the Electro Pulmonary Nodule Scan be used to assess lymphadenopathy (enlarged and/or inflamed lymph nodes?
The EPN Scan has not been studied in the evaluation of lymphandenopathy in the absence of a lung nodule. The EPN Scan has been developed and tested for use in the evaluation of lung nodules.
Are there contraindications to the Electro Pulmonary Nodule Scan?
The EPN Scan has not been assessed in patients with implanted electronic devices. Because the EPN Scan may be influenced by inflammation, patients with active infection, chronic inflammation or who are receiving high-dose systemic anti-inflammatory medication (i.e. corticosteroids) have been excluded from trials of the EPN Scan.
Does the Electro Pulmonary Nodule Scan provide an image of the nodule and surrounding tissue?
The EPN Scan does not produce an image and does not evaluate a single nodule, rather it assesses the bioconductance of the chest in patients with a nodule and produces a numerical score suggesting a higher risk of malignancy or increased likelihood of benignity.
What information is provided in an Electro Pulmonary Nodule Scan report?
The EPN Scan report provides a numeric score with an interpretation of that score relative to lung cancer risk.
What is sensitivity and specificity of the Electro Pulmonary Nodule Scan?
In a prospective study conducted at Johns Hopkins University School of Medicine, the EPN Scan discriminated between malignant lesions (29 primary lung cancers) and benign pathology (12) across a range of pulmonary nodules sizes (0.8 cm and greater) with a sensitivity of 89.7% (positive predictive value 96.3%) and specificity of 91.7% (negative predictive value 78.5%). According to this study, published in the Journal of Thoracic Oncology in April 2012, “The technology seems to be effective across a range of tumor thoracic locations, cell types, and stages.”
What is positive predictive value of the Electro Pulmonary Nodule Scan?
In a prospective study conducted at Johns Hopkins University School of Medicine and published in the Journal of Thoracic Oncology in April 2012, the EPN Scan discriminated between malignant lesions (29 primary lung cancers) and benign pathology (12) across a range of pulmonary nodules sizes (0.8 cm and greater) with a sensitivity of 89.7% (positive predictive value 96.3%) and specificity of 91.7% (negative predictive value 78.5%). This high positive predictive value of the EPN Scan to complement the high sensitivity and low specificity of LDCT screening and to expedite the further evaluation of potential malignancy.
What is the negative predictive value of the Electro Pulmonary Nodule Scan?
In a prospective study conducted at Johns Hopkins University School of Medicine and, published in the Journal of Thoracic Oncology in April 2012, the EPN Scan discriminated between malignant lesions (29 primary lung cancers) and benign pathology (12) across a range of pulmonary nodules sizes (0.8 cm and greater) with a sensitivity of 89.7% (positive predictive value 96.3%) and specificity of 91.7% (negative predictive value 78.5%). Because the EPN Scan was not designed as a screening test, the negative predictive value was developed to facilitate a higher specificity and positive predictive value. The EPN Scan is primarily designed to complement the high sensitivity and low specificity of CT screening and to expedite the further evaluation of potential malignancy.